The safety and toxicokinetics of SCH 721015, an adenovirus encoding the human interferon alpha-2b gene, and Syn3 (SCH 209702), a novel excipient, were assessed in cynomolgus monkeys administered intravesical doses of 2.5Â10E11 or 1.25Â10E13 particles SCH 721015 in 25 mg Syn3 or 25 mg Syn3 alone on study days 1 and 91. There was no systemic toxicity. Monkeys dosed with SCH 721015 in Syn3 were positive for SCH 721015-specific DNA in the urine for 2 to 3 days following each dose and had interferon alpha-2b protein in the urine for 1-3 days after a single dose and in fewer animals after a second dose. Intracystic administration was associated with inflammation and focal/multifocal ulceration in the urinary bladder and irritation in the ureters and urethra at necropsy. The physical trauma from catheterization and filling/emptying of the bladder was likely a contributing factor and Syn3 exacerbated the trauma. There was nearly complete resolution of these findings 2 months after the last dose. The trauma to the bladder likely contributed to low, transient systemic exposure to Syn3, SCH 721015 and human interferon protein. Keywords: adenovirus; interferon alpha-2b; monkey; bladder; intracystic; intravesical
INTRODUCTION
The American Cancer Society estimated that the incidence of new cases and deaths of urinary bladder cancer were 70 530 and 14 680, respectively, in 2010. 1 Superficial (or non-muscle invasive) bladder cancer can be treated with a transurethral resection of the bladder tumor via a cystoscope, often followed by intracystic (within the bladder) treatment with an adjuvant, immunotherapy or chemotherapy to reduce recurrence. The type of intracystic therapy depends on many factors but Bacillus Calmette-Guerin (BCG) immunotherapy has been the most common. BCG is a live attenuated strain of Mycobacterium tuberculosis that is instilled in the bladder for 1 to 2 h at a cycle of once weekly for 6 weeks, sometimes followed by an additional cycle and/or a maintenance schedule for up to a year. The mechanism of action for BCG involves a complex immunological reaction but is not fully known. 2 Transurethral resection of the bladder tumor followed by BCG is the most efficacious treatment option, but BCG treatment is associated with high toxicity. The side effects include lower urinary tract symptoms (for example, pain with urination), fever and flu-like symptoms, hematuria, skin rash, bladder contracture and urogenital-related infections, with B5% of patients treated with the standard dose (120 mg) experiencing moderate or severe side effects. Another rare but serious complication resulting from systemic exposure to BCG is sepsis that can in some cases lead to death. 3 Although BCG following transurethral resection of the bladder tumor is an effective treatment, other options are needed, given the toxicities, the number of patients who are unable to complete treatment (20%) and the number of patients who fail treatment or have recurrent disease within 5 years (30%). 4 Recombinant interferon alfa-2b (INTRON A) has pleiotropic effects that contribute to antitumor activity such as antiproliferative, apoptosis, angiogenesis inhibition, and immune augmentation. INTRON A is approved in the United States for the treatment of various cancers including malignant melanoma, hairy cell leukemia, non-Hodgkin's lymphoma and AIDS-related Kaposi's sarcoma. INTRON A is also approved in some countries for superficial bladder cancer, but not in the United States. As INTRON A is a protein administered by instilling in the bladder, the exposure period is limited to 1 to 2 h of instillation time. It is proposed that a gene therapy approach would essentially turn the bladder urothelium cells into bioreactors producing interferon alpha-2b protein to increase the exposure time and levels to potentially improve its efficacy. Studies in animal models support this hypothesis. [5] [6] [7] SCH 721015 is a recombinant replication-deficient adenovirus (type 5) with the coding sequence for interferon alpha-2b under the expression of the cytomegalovirus immediate-early promoter. The secreted interferon protein produced by SCH 721015 gene expression in urothelial cells is identical in sequence to INTRON A. The lumen surface of the bladder is covered by a glycosaminoglycan layer that protects the body from infections, as the urinary bladder is accessible to the exterior of the body. Syn3 (SCH 209702) is a novel excipient used with SCH 721015 to enhance delivery and transduction of the adenovirus to the bladder urothelium. 8, 9 The safety assessment of SCH 721015 needs to consider the potential systemic and localized toxicities of the expressed interferon alpha-2b, the adenoviral vector and Syn3. As noted above, the clinical safety of systemic and intracystic administration of interferon alpha-2b as INTRON A is well defined. The adenoviral backbone of SCH 721015 is identical to that of SCH 58500, an adenovirus containing the human p53 transgene. The adenoviral backbone, among other functions, encodes the outer protein coat of the virus and is responsible for the acute toxicities and tissue distribution of the virus itself. Therefore, the nonclinical and clinical experience with SCH 58500 is applicable to that of SCH 721015. SCH 58500 has been extensively studied in rodents 10 and Yorkshire pigs, 11 and has also been used in phase I and phase II/III clinical trials for the treatment of liver and ovarian cancer. 12 The clinical safety experience for SCH 58500 also includes a phase I study for the treatment of bladder cancer in which eight patients were treated with SCH 58500 in Big CHAP, a nonionic detergent. 13 SCH 58500 and Big CHAP were well tolerated and gene transfer was observed. A nonclinical intravesical study was conducted in Yorkshire pigs to support this phase I investigation (unpublished data, Schering-Plough Research Institute). The maximal dose was 3.75Â10E13 total particles in 20 mg ml -1 of Big CHAP and a total volume of 60 ml. There were no SCH 58500-or Big CHAP-related adverse findings. For Syn3, nonclinical safety assessment studies were conducted in rodents via intravenous and intracystic administration. There were no findings to limit its clinical use via intracystic administration. To fully evaluate the local and related systemic toxicity and biodistribution of SCH 721015 in Syn3, a toxicity and toxicokinetics study in monkeys was conducted via intracystic administration. The monkey is the only nonclinical model in which human interferon alpha-2b has pharmacological activity. This study was conducted to mimic the intended clinical regimen, and this paper details this study design and results.
RESULTS

Antemortem
There were no effects on the antemortem measurements including clinical observations, body weight, food consumption, ophthalmology, electrocardiograms, general veterinary examinations, serum chemistry, hematology, coagulation parameters, urinalysis or urine chemistry.
Plasma analysis for Syn3
SCH 209702 was quantifiable in plasma up to 7 or 25 h post initiation of instillation (Table 1) . Peak SCH 209702 plasma concentrations were generally achieved by B2 h. Individual T max values generally ranged from 1.5 or 2 h, although several monkeys (one monkey from day 1 and four monkeys from day 91) had T max values 42 h.
Individual SCH 209702 toxicokinetic parameters indicated that systemic exposure was independent of sex and was similar on both sampling days. The variability in SCH 209702 plasma concentrations and toxicokinetic parameters was high, and was likely influenced by the extent of trauma to the bladder (discussed under Necropsy and Histology). Therefore, mean SCH 209702 toxicokinetic parameters were also calculated based on trauma rather than by dose group. Monkeys were grouped according to whether or not histopathological findings were noted in the bladder, or whether or not there was occult blood in the urine (Tables 2 and 3 , respectively). Histopathological findings were defined as principally ulcers, but also with hemorrhage and mild congestion in one monkey each. In assessing the relationship between exposure and occult blood in the urine, animals were grouped by severity (negative, trace/small/moderate or large). Systemic exposure to SCH 209702, as measured by C max and area under the curve (AUC) values, was greater in monkeys for which either histopathological findings were noted in the bladder or occult blood was noted in the urine. The results indicate that systemic exposure to SCH 209702 was related to trauma and associated toxicity rather than to dose group.
Immunobiology for SCH 721015
Antiadenovirus antibodies were measured using a serum neutralizing factor (SNF) bioassay and an enzyme-linked immunosorbent assay (ELISA).
SNF levels during pretest were below the quantifiable level for all monkeys, with the exception of one monkey in the placebo control group. SNF levels in the placebo control group for the remaining intervals were quantifiable in a total of 2/6 monkeys, with only one monkey above quantifiable levels at any given interval. There were 7/10 to 9/10 monkeys in the high-dose group that had quantifiable levels of SNFs to SCH 721015 at each time point after the first dose, whereas only half of the monkeys in the low-dose group had quantifiable levels. All monkeys in both groups had quantifiable levels after the second dose. SNFs were quantifiable at all intervals measured including week 12 and day 148. The neutralizing potency was generally comparable between the low-and high-dose groups within each interval.
The mean antiadenoviral antibody titers measured by ELISA were similar among all groups during pretest (163-487) and were also similar in the placebo control group throughout the study (163-334). The results demonstrated an increase in antibody titer to adenovirus after the first dose for both the low-and high-dose groups. The high-dose group averaged higher antiadenoviral titers for every time point from day 15 through day 98 than the low-dose group. The highdose group averaged its highest antiadenoviral titer on day 36 (36 477) and the low-dose group averaged its highest on day 98 (7084), which was after the second dose on day 91. The titers were generally comparable between both groups for days 105 through 148 (3028-5321). The quicker and generally higher response in the high-dose group was expected given the higher adenoviral dose in this group.
Immunobiology for interferon
Antibodies against human interferon alpha-2b were measured in the serum using a Biosensor based assay (BIACORE, GE Healthcare Life Sciences, Piscataway, NJ, USA). Antibodies were not detected during pretest with the exception of one monkey in the low-dose group. Antibodies were also not detected at any interval in the placebo control group with the exception of one monkey for week 12.
There were 8/10 of monkeys in the high-dose group that developed antibodies against interferon alpha-2b after a single dose compared with about half of the monkeys in the low-dose group. After the second dose, there were 9/10 and 7/10 monkeys positive in the highand low-dose groups, respectively. The antibody response after a second dose was more consistent and sustained in the high-dose group than in the low-dose group. A positive correlation between the presence of antibodies against interferon and interferon protein levels in the serum was also more evident in the high-dose group than the low-dose group after each dose.
Analysis for SCH 721015-specific DNA SCH 721015-specific DNA was measured in whole blood, bladder and selected tissues and urine using PCR.
Whole blood. All monkeys were negative for SCH 721015-specific DNA in whole blood during the pretest period, and the placebo control group was negative for all study intervals. SCH 721015-specific DNA in the whole blood was quantifiable, but at low levels, during the first 24 h after each dose in a limited number of monkeys in the lowdose group (2/16 and 1/10 monkeys for the respective doses) and in approximately two-thirds of the monkeys in the high-dose group (11/16 and 7/10, respectively). The SCH 721015-specific DNA results were similar within each group after the first and second dose. Copies of SCH 721015-specific DNA were identified in blood as early as 0.5 h post instillation (first sampling interval) in the high-dose group. Approximately two-thirds of the monkeys in this group had 10E4 (near the lower limit of quantification) to 6.34Â10E6 copies per ml of blood over a 24 h post-instillation period. The low-dose group was exposed to B100-fold fewer particles than the high-dose group, and exposure to particles of SCH 721015 was less than the lower limit of quantification for the majority of the monkeys. SCH 721015-specific DNA levels in the blood for all monkeys were below quantifiable levels for the remaining sampling intervals that included days 8, 15, 98 and 148 with one exception. One monkey in the high-dose group had levels near the lower limit of quantification (2.59Â10E4 copies DNA per ml) on day 98.
Bladder tissue. SCH 721015-specific DNA in the bladder tissue of the placebo control group was not detectable or below quantifiable levels with one exception. One monkey in the placebo control group had a low level of SCH 721015-specific DNA on day 8 (152 copies DNA per mg total DNA), presumably from inadvertent contamination at the time of sampling. All monkeys in the low-and high-dose groups had SCH 721015-specific DNA in the bladder tissue at necropsy on days 8 and 98 (or 7 days after the first and second doses, respectively). The levels were higher in the high-dose group compared with the low-dose group, but the levels were comparable within each group between days 8 and 98. The range of values in the high-dose group were B4Â10E4-9Â10E5 copies DNA per mg of total DNA compared with B175-4Â10E4 copies DNA per mg of total DNA in the low-dose group. SCH 721015-specific DNA in the bladder tissue of the high-dose group was below quantifiable levels at necropsy on day 148 (or B60 days after the second dose). However, SCH 721015-specific DNA was detected in the bladder tissue of 2/4 monkeys in the low-dose group at this interval. The value in one of these monkeys was similar to that seen in one placebo control monkey on day 8 and may have been related to contamination. The value in the other low-dose group monkey (1.37Â10E5 copies DNA per mg of total DNA) was higher than previously seen in this group and was also comparable to the values of the high-dose group at earlier intervals. The reason for this high level of SCH 721015-specific DNA in this monkey was not determined, but there were no quantifiable levels in all four high-dose group monkeys at this interval.
Other tissues. SCH 721015-specific DNA was detected in a limited number of monkeys in the liver, kidney and gonad. The highest levels in these tissues correlated with the high levels of SCH 721015-specific DNA in whole blood, but a correlation was not clearly evident at lower tissue levels. In the low-dose group, SCH 721015 was detected in the kidney of one monkey and the liver of two monkeys. SCH 721015-specific DNA in the kidney was detected on day 148 at 905 copies and in the liver on day 8 at p174 copies DNA per mg of total tissue DNA.
In the high-dose group, SCH 721015 was detected in the liver and kidneys of 5 and 3 monkeys, respectively, on days 8 and 98. The monkey with the highest DNA levels in the kidney (2515 copies DNA per mg of total tissue DNA) also had the highest whole blood and liver DNA levels after a single dose (3.1Â10E6 and 8762 copies DNA per mg of total tissue DNA). In addition, this monkey also had SCH 721015-specific DNA in the ovary (1.15Â10E4 copies DNA per mg of total tissue DNA). The DNA level in the kidney of the other monkeys was considerably lower (p120 copies) and did not clearly correlate with the systemic DNA levels. The potential for retrograde exposure from the bladder (site of dose administration) to the kidney could not be ruled out. One male was positive for SCH 721015-specific DNA in the testis but the DNA level was near the limit of quantitation. This male also had the second highest whole blood and liver DNA levels after a single dose (2.08Â10E6 and 3055 copies, respectively). DNA in the liver for one monkey was 1548 copies on day 98 and this monkey had the highest whole blood DNA levels after the second dose (6.34Â10E6 copies). DNA was detected in the liver at considerably lower levels in only two other monkeys (p40 copies), but did not clearly correlate with the whole blood levels. DNA was not detected in the liver, kidney or gonad on day 148.
Urine. All monkeys were negative for SCH 721015-specific DNA in the urine during the pretest period, with the exception of one monkey in the high-dose group. This monkey was in the last set of monkeys dosed. Some monkeys in the placebo control group and SCH 209702 control group were also positive for SCH 721015-specific DNA during the study (41/208 samples). The assay detects SCH 721015-specific DNA and not replication-competent adenovirus. Therefore, these samples were positive presumably because of contamination during the assay or at the time of sampling (for example, from the urine collection pan). The majority of the monkeys in the low-and highdose groups were positive for SCH 721015-specific DNA on the days of dosing (days 1 and 91). Most monkeys remained positive for the following 2 or 3 days in the low-and high-dose groups, respectively. There were only 1 or 2 monkeys positive in each of these groups on days 15 and 105, but the incidence could not be definitively attributed to the test article(s) as it was comparable to the false positives in the control groups. None of the monkeys in the low-or high-dose group 7were positive on week 12, which was prior to the second dose.
Interferon protein expression in serum (ECL Assay) and urine (ELISA) Human interferon alpha-2b protein expression was measured in serum using an electrochemiluminescent (ECL) assay and in urine using an ELISA. Interferon alpha-2b was detected in the serum following the first intracystic administration in all monkeys in the high-dose group and about half of the monkeys in the low-dose group (Table 4) . The serum levels in the high-dose group were a maximum of 59 417, 20 250 and 5200 IU ml -1 for days 2, 3 and 4, respectively. The serum levels in the low-dose group for these respective days were a maximum of 2250, 330 and 113 IU ml -1 . The number of monkeys with serum interferon levels also declined on day 8 and only a few monkeys in each group had serum levels on day 15. Interferon was detected in the serum following the second dose on day 91 in about half of the monkeys in the low-and high-dose groups. There was no association between serum interferon levels and interferon or adenoviral antibodies. One monkey in the highdose group had 303 000, 163 000 and 66 250 IU ml -1 on days 92, 93, and 94, respectively. The maximum serum level in the remaining high-dose monkeys was 13 000 IU ml -1 on day 92. The maximum serum level in the low-dose group was 127 IU ml -1 on day 92. All monkeys had near or below background levels on day 98.
A total of 91% of the monkeys administered SCH 721015 in SCH 209702 had measurable levels of interferon alpha-2b in the urine after a single dose. Interferon alpha-2b could be detected in urine specimens collected 1-3 days after dosing (Table 5) . In a few instances, interferon alpha-2b was detected 14 days after the initial dose, and one low-dose sample had detectable levels at the interval prior to the second dose (week 12). Of the 10 monkeys re-dosed in the low-dose group, 6 expressed measurable amounts of interferon alpha-2b in urine for one or more intervals after re-dosing. Of these monkeys, three had detectable levels of interferon alpha-2b on study days 92-94. Of the 10 monkeys re-dosed in the high-dose group, 9 expressed measurable amounts of interferon alpha-2b in urine for one or more intervals. Of these monkeys, seven had detectable levels of interferon alpha-2b on days 92-94. Interferon alpha-2b was not detected in any sample on day 105, which was the last sampling interval. Interferon alpha-2b was detected by ELISA in the urine of only 3 of 240 specimens (o1.5%) in the placebo and SCH 209702 control group. The ELISA detects certain human interferon alpha subtypes in addition to human interferon alpha 2b but does not detect human interferon beta or interferon gamma, nor does it detect the mouse or rat interferons alpha, beta or gamma. Given that no other samples from the three animals were positive for interferon alpha protein, it is possible that these urine samples became contaminated during handling (during collection and addition of the stabilization buffer or during assay).
Necropsy and histology
Monkeys were necropsied on days 8 and 98, which were 8 days after the first and second doses, respectively, and also on day 148, which was B2 months after the second dose. The test article-related findings were limited to macroscopic findings in the urinary bladder and histological findings in the urinary bladder, urethra and ureter in the SCH 209702 control group and the SCH 721015-dosed groups.
The bladders were opened and examined at necropsy on day 8 and fixed in formalin prior to opening and macroscopic examination for the subsequent necropsies. The macroscopic findings in the bladder included red discoloration/foci, transmural red foci and thickness increased with white or yellow plaques at necropsy on day 8 and discoloration/foci on day 98. There were no macroscopic findings in the bladder on day 148 and no macroscopic findings in the urethra or ureter at any necropsy interval.
The incidence of bladder thickness increased on day 8 (prior to fixation) was comparable between the SCH 209702 control group and SCH 721015 low-and high-dose groups; 1/6, 1/6 and 2/6 monkeys, respectively. These monkeys generally had red discoloration of the mucosa and one monkey each in the low-and high-dose groups had a red transmural foci. Red discoloration of the mucosa (focal or multifocal) was also observed in 2/6, 1/6 and 2/6 monkeys, respectively. Upon histological examination, the monkeys with thickness increased were found to have a focal or multifocal ulceration of the bladder that was of mild severity except for one monkey with a transmural focus in the low-dose group in which the ulcer was of a moderate severity (Table 6 and Figure 1 ). Submucosal inflammation, evident by mononuclear cell infiltration, was present in 2/6 placebo control (minimal) and in all monkeys in the SCH 209702 control and SCH 721015-dosed groups (minimal to mild). The severity of the inflammation was minimal except for 1/6 monkeys in the SCH 209702 control and low-dose group and 5/6 monkeys in the high-dose group in which the inflammation was mild. The slightly greater severity of inflammation in the high-dose group was expected given the higher adenoviral dose. Histological findings in the urethra included a minimal mononuclear cell infiltrate in the lamina propria and/or submucosa in 2/4, 3/5 and 3/5 monkeys in the SCH 209702 control, low-dose and high-dose groups, respectively. One of these monkeys in the SCH 209702-control group also had minimal infiltration and hyperplasia of the urothelium. The incidence of discoloration/foci in the bladder on day 98 (fixed) was comparable between the SCH 209702 control and SCH 721015 low-and high-dose groups: 2/6, 1/6 and 2/6 monkeys, respectively. The incidence and/or severity of the histological findings in the bladder from the second dose was generally similar to those from the necropsy after the first dose, but also included urothelial cytoplasmic vacuolation, chronic infiltration and/or hyperplasia (Table 7) . Focal or multifocal ulcers were found in 2/6 monkeys in the low-dose and high-dose groups. The ulcers were of minimal severity except for a mild ulcer in one of the high-dose monkeys. There was also a minimal to moderate chronic inflammation of the tunica muscularis in the high-dose male monkeys. Most often, this chronic inflammation was not accompanied by overlying ulceration of the urothelium; however, the location and extent of the finding suggest that it was associated with a healed ulcer or an ulcer not included in the histological samples. The focal distribution and nature of the findings suggest that they were procedurally related. Urothelial hyperplasia (minimal to mild) was noted in 1/6, 3/6 and 5/6 monkeys in the SCH 209702 control and SCH 721015 low-and high-dose groups, respectively. In the urethral urothelium or lamina propria/submucosa, mixed cell and/or mononuclear cell inflammation was noted in 2/6, 2/6 and 3/6 monkeys in the SCH 209702 control and SCH 721015 low-and high-dose groups, respectively. One of the monkeys in the high-dose group was also found to have minimal cytoplasmic vacuolation in the urethra. Histological findings in the ureters were limited to 2/6 monkeys in the low-dose group and included minimal mononuclear cell infiltration of the lamina propria in both monkeys and cytoplasmic vacuolation at the opening into the urinary bladder in one monkey.
At the day 148 necropsy, which was B2 months after the second dose, there were no macroscopic findings in the urinary bladder and all histopathological findings were minimal in severity and usually A mild ulcer (arrow) is present that has a transmural extension to the serosa (not shown in the photographs) with perivascular minimal/mild perivascular edema and mixed cellular infiltrate. There is also a diffuse suburothelial minimal mixed cellular infiltrate (eosinophils, neutrophils and lymphocytes) and lamina propria/submucosal multifocal perivascular minimal mixed cellular infiltrate with occasional thickening of the media of arterioles (arrowhead). These findings correlate with the necropsy findings of bladder mucosa abnormal appearance, thickness increased with white plaque and multifocal mild redness. (c) SCH 721015 low-dose (group T1 male, 2.5E11 particles of SCH 721015 in 25 mg SCH 209702). A moderate ulcer (arrow) associated with transmural inflammation is present. Moderate was highest severity for the ulcers observed in the study. In the nonulcerated areas, there is suburothelial diffuse minimal lymphocytic infiltrate with rare foci of hemorrhage (star). Deeper in the lamina propria there is minimal perivascular edema and lymphocytic infiltration and thickening of the media of small arterioles (arrowhead). These findings correlate with the necropsy findings of abnormal appearance, thickness increased with yellow plaque.
confined to the urothelium of the urinary bladder and/or urethra (Table 8 ). In the urothelium of the bladder, findings included cytoplasmic vacuolation in 1/4, 1/4 and 2/4 monkeys in the SCH 209702 control, low-dose and high-dose groups, respectively. Mononuclear cell infiltration in the urothelium or submucosa was found in 1/4 and 3/4 monkeys in the low-and high-dose groups, respectively. Minimal fibrosis was also found in the lamina propria of the bladder of 1/4 monkeys in each the low-and high-dose groups. In the urethral urothelium or lamina propria/submucosa, mononuclear cell infiltration was found in 1/4, 1/4 and 3/4 monkeys in the SCH 209702 control and SCH 721015 low-and high-dose groups, respectively. The histological evidence indicates that reversal of findings was nearly complete in the recovery groups with minimal residual evidence of irritation.
DISCUSSION
The primary objective of this study was to assess the toxicity and exposure of SCH 721015, an adenovirus vector encoding the human interferon alpha-2b gene, SCH 209702, a novel excipient, and of the expressed interferon alpha-2b protein following intracystic administration of SCH 721015 and SCH 209702 to cynomolgus monkeys on study days 1 and 91. Post-mortem evaluations were on days 8, 98 or 148. Nonclinical pharmacological studies in rats demonstrated that longer intervals between doses of SCH 721015 allowed for recovery of interferon alpha-2b protein expression after administration intravesically into the bladder. 14 Urinary interferon alpha-2b was measured in rats given three intravesical doses of SCH 721015 at various intervals (30, 45, 60 and 90 days). Increasing the interval between two doses correlated with increased urinary interferon alpha-2b concentrations. After a third dose, urinary interferon alpha-2b was only detectable at a 90-day interval between administrations. Hence, the period between doses in the present monkey study was selected to be 90 days. Consistent with expression in rat, in this monkey study, the urinary interferon alpha-2b concentration detected was B10-fold lower than that detected after the initial dose. Nonetheless, the interferon alpha-2b level in the bladder tissue would be 10-to 100-fold higher than that detected after a single dose of INTRON A protein, a level that has demonstrated clinical activity. The loss of interferon expression after SCH 721015 administration at the second dose is likely due to the expected cellular immune response.
Intracystic administration of SCH 209702 alone and SCH 721015 in SCH 209702 generally resulted in inflammation and ulceration of the bladder and irritation of the ureters and urethra. The ulceration was focal/multifocal and of mild severity, except for one case that was moderate. Nearly complete recovery of the findings was evident after B2 months. The findings were only limited to or near the site of administration and there were no findings in other urogenital organs or systemic toxicity.
There was a correlation between the urinary bladder findings and systemic exposure. The T max of the SCH 209702 plasma levels occurred after the dose was voided and the catheter was removed from the bladder. Systemic exposure to SCH 209702, as measured by C max and AUC values, was greater in monkeys for which histopathological findings were noted in the bladder (ulcers, hemorrhage and mild congestion), or for which occult blood was noted in the urine. The results indicate that systemic exposure to SCH 209702 was related to trauma and associated toxicity. Serum interferon levels did not show a clear correlation with bladder trauma. However, there was a reasonable correlation between the SCH 721015 DNA levels in the blood, ulcers and the serum interferon levels. Of the four monkeys in the high-dose group that had ulcers, three were among those with the highest amount of SCH 721015 DNA in the blood. Monkeys with SCH 721015-specific DNA in the blood after the first dose had above background levels of serum interferon. The two monkeys in the lowdose group with SCH 721015-specific DNA levels in the blood had the highest serum interferon levels in their group. Those monkeys with higher SCH 721015-specific DNA levels in the blood tended to also have higher serum interferon levels. A correlation between SCH 721015-specific DNA and serum interferon was less evident after the second dose and this may have been a function of SNFs or antibodies to SCH 721015.
The monkeys with the highest serum interferon level after the first and second doses (59 417 and 303 000 IU ml -1 ) also had an ulcer, the highest amount of SCH 721015-specific DNA in the blood (3.41Â10E6 and 6.34Â10E6 copies DNA per ml) and high exposure to SCH 209702 (AUC (tf) ¼141 000 and 428 000 ng h ml -1 ).
Taken together, the trauma to the urinary bladder from the catheterization procedure in the presence of SCH 209702 was found to cause ulceration and likely contributed to the systemic exposures of SCH 209702, SCH 721015 and the expressed human interferon protein. However, there was no systemic toxicity in any of the animals. The ulceration and other histopathological findings nearly resolved within 2 months after the final dose. Overall, the results of this study support the clinical investigation of SCH 721015 in SCH 209702.
MATERIALS AND METHODS
This study was conducted in compliance with Good Laboratory Practice regulations, 15 with the exception of some prestudy activities and some bioanalytical (PCR of urine and tissue and CPE). Treatment of the animals was in accordance with the regulations outlined in the USDA (United States Department of Agriculture) Animal Welfare Act (9 CFR, parts 1-3) and the conditions specified in the Guide for the Care and Use of Laboratory Animals. 16 The study protocol was approved by the facility's animal care and use committee.
Animal husbandry
Purpose-bred and naive cynomolgus monkeys (Macaca fascicularis) were imported from China via Scientific Resources International Ltd (Reno, NV, USA) and Primate Products (Miami, FL, USA). The monkeys underwent the Centers for Disease Control and Prevention's mandatory 30-day quarantine period and at least a 7-day prestudy acclimation period. Age ranges were between 2.6 and 5.9 years (males) and 2.8 and 6.1 years (females). The monkeys were housed individually and enclosures were as specified in the USDA Animal Welfare Act (9 CFR, parts 1-3) and as described in the Guide for the Care and Use of Laboratory Animals. 16 Certified Purina Primate Diet (PMI Nutrition International, Richmond, IN, USA) was provided daily and supplemented with fruit or vegetables two to three times weekly. Also, additional food items were given to the animals as part of the environmental enrichment program. Tap water was available ad libitum to each animal.
Test and control articles
SCH 721015 (rAd-IFN) is a replication-deficient recombinant adenovirus (type 5) with deletions in the E1a/E1b regions and protein IX. The deleted sequences were replaced with the code for the cytomegalovirus immediate-early promoter and human interferon alpha-2b. Details on the SCH 721015 construct has been reported previously. 17 There were a total of 30 male and 30 female monkeys in the study. In the single-dose portion of the study, there were three monkeys per group per sex. Monkeys in the single-dose portion were dosed on day 1 and necropsied on day 8. In the re-dose portion of the study, there were three monkeys per group per sex in the placebo control group and five monkeys per group per sex in the remaining dose groups. Monkeys in the re-dose portion were dosed on days 1 and 91 and then necropsied as follows: three monkeys per sex in groups C2, T1 and T2 were necropsied on day 98 and the remaining two monkeys per sex in these groups were necropsied on day 148 (2 months post re-dose).
Dose volume
A method development study was conducted separately to determine the appropriate intracystic dose volume to monkeys. The bladder was filled with 45 ml of contrast media and radiographs taken at volumes of 45, 35, 25 and 15 ml. The bladder was full at 45 ml and some blood was present in the catheter. The bladder did not notably differ in size from volumes of 45-25 ml but was notably smaller in size at 15 ml. A dose volume of 25 ml was selected for the present study as it was the minimal volume to full the bladder and also allowed space for urine production over the 1 h dwell time.
Intracystic administration
To facilitate filling and voiding the bladder, female monkeys were fitted with a Fogarty, 3 French, Thru-lumen Embolectomy Catheter (Edwards Lifesciences, Irvine, CA, USA) and male monkeys were fitted with a Kendall-Curity 5 French feeding tube (Mansfield, MA, USA). Monkeys were initially sedated using ketamine (10 mg kg -1 , intramuscular). A bolus intravenous dose of propofol (2.5 mg kg -1 ) was administered followed immediately by a continuous infusion of propofol at a rate of 0.4-1.0 mg kg -1 min -1 for the duration of the dosing procedure to maintain an appropriate plane of anesthesia. Monkeys were monitored throughout the sedation period by assessing heart rate, respiratory rate, body temperature and pulse oximetry.
The bladder was flushed and voided using phosphate-buffered saline at 37 ± 4 1C. Monkeys were then administered the intracystic dose at a volume of 25 ml and the instilled dose was left in the bladder for 60 min (dwell time).
Antemortem measurements
Each monkey was observed once each morning and afternoon throughout the study for changes in general appearance and behavior. Body weights were measured approximately weekly and food consumption was qualitatively assessed daily. Ophthalmic examinations were conducted once pretest, day 5±1 and day 95 ± 1 and included focal illumination, indirect ophthalmoscopy and slit lamp biomicroscopy. Electrocardiogram measurements were taken twice pretest, day 5, week 12 and day 95. General veterinary examinations were conducted twice pretest and 4 days after each dose. Serum chemistry, hematology and coagulation parameters were evaluated twice pretest, day 6, day 15, week 12, day 95, day 105 and day 148. Urinalysis and urine chemistry were conducted twice pretest, day -7, day 5, day 15, week 7, week 12, day 95, day 105 and day 148.
Plasma analysis for SCH 209702
Blood was collected from the monkeys in the single-dose portion on week -1 and on day 1 at 0.5, 1, 2, 3, 4, 6 and 24 h after the dwell period and on day 8. Blood was collected from the monkeys in the re-dose portion on weeks -1 and 12 and on day 91 at 0.5, 1, 2, 3, 4, 6 and 24 h after the dwell period and on day 98. Blood was collected into tubes containing EDTA and processed to obtain plasma that was then stored in a -70 1C freezer or colder. Samples from placebo control monkeys (C1) were discarded without analysis. The remaining samples were assayed for SCH 209702 using liquid chromatography coupled to tandem mass spectrometry.
Immunobiology for SCH 721015 and interferon
Blood was collected and processed in a sterile manner to obtain serum from the monkeys in the re-dose portion on day -7, day 15, day 22, day 36, week 12, day 98, day 105, day 112, day 126 and day 148. Samples from the SCH 209702 control group (C2) were discarded without analysis. The remaining samples were stored in a -70 1C freezer or colder until analyzed for: (1) SCH 721015 antibodies by an ELISA and a SNF bioassay and (2) human interferon alpha-2b antibodies using a biosensor-based assay.
Whole blood analysis for SCH 721015 (PCR)
Blood was collected in EDTA (K3) tubes from the monkeys in the single-dose portion on week -1, on day 1 at 0.5, 1, 2, 3, 4, 6 and 24 h after the dwell period and on day 8. Blood was also collected from the monkeys in the re-dose portion on week -1, on day 1 at 0.5, 1, 2, 3, 4, 6 and 24 h after the dwell period, day 8, day 15, week 12, on day 91 at 0.5, 1, 2, 3, 4, 6 and 24 h after the dwell period, day 98 and day 148. Samples from the SCH 209702 control group (C2) were discarded without analysis. The remaining samples were kept on ice, aliquoted to sterile cryovials in a sterile manner within 5 h of collection and then frozen and stored in a -70 1C freezer or colder. Whole blood samples were assayed for SCH 721015-specific DNA by PCR analysis.
Serum analysis for interferon protein (ECL immunoassay and cytopathic effect assay)
Blood was collected and processed to serum from monkeys in the single-dose portion on week -1, day 2, day 3, day 4 and day 8. Blood was also collected and processed from the monkeys in the re-dose portion on week -1, day 2, day 3, day 4, day 8, day 15, week 12, day 92, day 93, day 94 and day 98. Serum was stored in a -70 1C freezer or colder until analyzed for human interferon alpha2b protein by an ECL immunoassay and bioactivity by a cytopathic effect assay.
Urine analysis for SCH 721015 (PCR) and interferon protein (ELISA)
Urine was collected from all monkeys once predose and on days 1-4. Urine was also collected from the monkeys in the re-dose portion on day 15, week 12, days 91-94 and day 105. The predose sample may have been collected directly from the bladder prior to dose administration and all other urine samples were collected by cage run-off at room temperature for a duration adequate to collect B3 ml of urine. Urine was collected periodically in 1 ml aliquots and placed in containers with 0.1 ml of a 10% bovine serum albumin in 50 mM HEPES buffer. Urine samples were stored in a À70 1C freezer or colder until analyzed for SCH 721015 DNA by PCR and human interferon alpha-2b protein by ELISA. The concentration of interferon alpha-2b in the urine samples determined by ELISA represents the concentration in each sample before it was diluted with 0.1 ml of the bovine serum albumin in HEPES-stabilizing buffer. The total urine volume for the corresponding 24-h intervals was not measured and the concentrations were not adjusted for hydration level. The following formula was used to calculate the volume-adjusted interferon alpha-2b urine concentration:
Adjusted interferon alpha-2b (IFN) concentration¼((raw IFN concentration)Â(initial volume)/((initial volume)-(0.1))).
Tissue analysis for SCH 721015 (PCR)
Samples up to three aliquots at B50 mg each were collected from the urinary bladder, liver, kidney ovaries and testis (right). Sterile instruments and methods were used to avoid contamination. Samples were not collected from the SCH 209702 control group (C2). For the bladder, four small tissue samples were collected as described under necropsy. The samples were frozen in liquid nitrogen and stored in a À70 1C freezer or colder until analyzed for SCH 721015 DNA by PCR. For the ovaries, samples up to three aliquots at B50 mg each were collected from the right and left ovaries but the size of the sample did not exceed approximately half of the total ovary weight. Gonads from groups C1 and T2 for day 8 and from T2 for day 198 were analyzed.
Monkeys were necropsied on days 8, 98 or 148. Monkeys were exsanguinated for necropsy while under deep anesthesia induced with ketamine and Beuthanasia-D (Schering-Plough Animal Health, Summit, NJ, USA). A total of 42 tissues/organs were collected and preserved in neutral-buffered 10% formalin except for the eyes, which were preserved in Davidson's solution.
Any urethra or ureters present on the bladder or kidney from the day 8 necropsy were separately processed for microscopic examination. The entire length of the ureters and a portion of the urethra attached to the urinary bladder were collected for the day 98 and 148 necropsies. The following portions of the urethra were also collected for examination: the prostatic and penile urethra for males and a middle portion of the urethra for females. The bladder was marked on the middle of the ventral surface. The bladder was incised longitudinally along the right side to separate, but not completely open, the dorsal and ventral surfaces. Four small tissue samples of the bladder were collected for PCR analysis from the middle along the cut surface. The PCR sample was not taken from a gross lesion. Instead, if necessary, another region may have been sampled. Each ureter was cut into three portions: (1) proximal to kidney, (2) middle ureter and (3) proximal to bladder. Representative sections from each portion of the ureter were processed for microscopic examination.
Organs/tissues and gross findings were processed to slides and stained with hematoxylin and eosin. The bladder was also stained separately with acid fast stain, gram stain, Masson's trichrome stain (selected monkeys in each group) and alizarin red stain (group C2 only).
All processed organs/tissues and gross findings were examined microscopically except for group T1 and the necropsies on day 148. For group T1, only the bladder, ureter, urethra, kidneys, target organs and gross findings were examined microscopically. For necropsies on day 148, only bladders, target organs and gross findings were examined.
The following organs were weighed and organ-to-body weight ratios were calculated: adrenal glands, brain, epididymides, heart, kidneys, liver, lungs, ovaries, pituitary gland (post fixation), prostate gland, spleen, testes, thymus, thyroid gland/parathyroid glands and uterus (plus cervix).
